Meta-analysis of anti-vascular endothelial growth factor combined with photodynamic therapy in treatment of age-related macular degeneration

Journal of Shanghai Jiaotong University (Medical Science)

Volumn 32, Issue 12, 2012, Pages 1621-1627

  Zhou, Jia ^a   Lu, Qiong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Age related macular degeneration; Anti vascular endothelial growth factor; Combination therapy; Verteporfin photodynamic therapy

Indexed keywords

RECOMBINANT VASCULOTROPIN;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EYE EXAMINATION; HUMAN; META ANALYSIS; MONOTHERAPY; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; SYSTEMATIC REVIEW; VISUAL ACUITY;

EID: 84874389082     PISSN: 16748115     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1674-8115.2012.12.021     Document Type: Article

References (14)

1. Ambati J, Ambati B K, Yoo S H, et al. Age-related macular degeneration: etiology, pathogenesis and therapeutic strategies[J]. Surv Ophthalmol, 2003, 48(3): 257-293.
2. 2005, 41(1): 15-19.
3. Bressler N M, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials: TAP report 2[J]. Arch Ophthalmol, 2001, 119(2): 198-207.
4. Bashshur Z F, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration[J]. Am J Ophthalmol, 2006, 142(1): 1-9.
5. Wormald R, Evans J, Smeeth L, et al. Photodynamic therapy for neovascular age-related macular degeneration[J]. Cochrane Database Syst Rev, 2007, 18(3): CD002030.
6. Heier J S, Boyer D S, Ciulla T A, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study[J]. Arch Ophthalmol, 2006, 124(11): 1532-1542.
7. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration[J]. Ophthalmology, 2007, 114(6): 1179-1185.
8. Antoszyk A N, Tuomi L, Chung C Y, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results[J]. Am J Ophthalmol, 2008, 145(5): 862-874.
9. Costagliola C, Romano M, Rinaldi M, et al. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration[J]. Br J Ophthalmol, 2010, 94(2): 180-184.
10. Potter M J, Claudio C C, Szabo S M. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study[J]. Br J Ophthalmol, 2010, 94(2): 174-179.
11. Bashshur Z F, Schakal A R, El-Mollayess G M, et al. Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration[J]. Retina, 2011, 31(4): 636-644.
12. Vallance J H, Johnson B, Majid M A, et al. A randomized prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration[J]. Eye (Lond), 2010, 24(10): 1561-1567.
13. Rosenfeld P J, Brown D M, Heier J S, et al. Ranibizumab for neovascular age-related macular degeneration[J]. N Engl J Med, 2006, 355(14): 1419-1431.
14. Brown D M, Kaiser P K, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration[J]. N Engl J Med, 2006, 355(14): 1432-1444.